To celebrate the heroic efforts from members of our community and to spread awareness about ependymoma, the CERN Foundation created a 2020 calendar featuring inspiration stories, disease information, and CERN programs to inspire, influence and impact others.

"This calendar is a visual reminder for us to encourage and support each other no matter what role we play in the ependymoma community. We all have different backgrounds, different perspectives, and different journeys with this rare disease, but we are in this together and can understand each other like very few others are able to do.” - Kim Wallgren, President of the CERN Foundation.

For a donation of $25 (or more!), you will receive a calendar mailed directly to you! A perfect gift for the holidays. Profits raised from this campaign will allow us to continue the important programs we offer (including awareness, education, and supported research efforts) to the ependymoma community.

Thank you to the Thomas Reynolds Foundation, Glass Solutions, Inc., the Robert Connor Dawes Foundation and Aermacchi Haynes-Varese Land Speed Racing for sponsoring the 2020 CERN calendar. Because of our generous sponsors, all donations over $25 will receive a calendar shipped directly to your home for no additional fee!

You can also download a free printable gift tag to use if giving the calendar to someone else as a gift! Thank you again for your support. 
 

CERN fellowship recipient, Dr. Kristian Pajtler, and collaborators, have made important discoveries. They studied YAP1 fusion-positive supratentorial ependymomas to determine the molecular mechanisms of oncogenesis (genetic changes that have the potential to cause cancer). They discovered YAP1-MAMLD1 fusion functions as an oncogenic driver of ependymoma through recruitment of TEADs and NFIs, indicating the need for preclinical studies to block the interaction between YAP1 fusions and NFI and TEAD transcription factors.

READ MORE

In addition, the team recently identified a novel molecular group of spinal ependymoma with MYCN amplification and plans to establish it as a new molecular subgroup in ependymoma. 

READ MORE